Federal subpoenas are latest in opioid actions.
Formulary Watch
Latest News
All News
Advertisement
FDA cites 15 companies making unsubstantiated health claims.
PBM mergers contribute to pricing problems, ACP says.
Trump claims lower drug prices, fights Pelosi bill.
FDA and Congress are putting forth new proposals to mitigate drug shortages, which continue to have a major impact on the US healthcare system.
Pharma maker develops biosimilars to Lucentis, Eyelea.
Sandoz now has 2 biosimilars to the popular cancer drug.
Health groups had urged Trump to make a different choice.
PBM’s Medicare plan includes deep discounts
Researchers find lower lung function after inhaler change.
Advertisement
This is the eighth indication approved for Xarelto.
Here are the most exciting drugs in the pipeline right now.
Drug is the only respiratory therapy that can be given at home every 8 weeks.
New HIV prevention drug not indicated for women.
Drugstore retailers pull ranitidine and Zantac products off the shelves due to cancer concerns.
Drug is first 8-week treatment approved for this type of HCV.
How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.
FDA limits packaging for this OTC medication.
Fentanyl citrate and ephedrine sulfate are among the medications affected.
FDA is evaluating risks to patients.
Targeted therapy gives new hope to patients with an aggressive form of lung cancer.
Health groups urge Trump to appoint Acting FDA Commissioner Ned Sharpless.
The new drug is an add-on to levodopa/carbidopa for Parkinson’s patients experiencing “off” episodes.
Use of these meds to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in liver failure in rare cases.
Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.
DEA scrambles to add qualified marijuana growers.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
Prior authorization isn’t shrinking. Its savings are
5